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Purpose: Both end-stage renal disease and diabetes have been demonstrated to have a 
negative effect on the outcome of infrainguinal arterial reconstruction, primarily because 
of increased perioperative morbidity and wound complications. This study was under- 
taken to determine whether the combination of these comorbid factors affects the out- 
come of distal arterial reconstruction. 
Methods: Eighty-three distal lower extremity arterial bypasses originating from the 
femoral artery and terminating at the peroneal, anterior, or posterior dbial artery were 
performed on 76 patients over a 5-year period at a tertiary care medical center. Autoge- 
nous greater saphenous vein was used as the bypass conduit in all instances. Combined 
inflow and composite vein procedures were excluded. 
Results: There was one perioperative d ath, for a mortality rate of 1.2%. The diabetes 
mellitus (DM) plus end-stage renal disease (DM+ESRD) cohort displayed a significant- 
ly lower 1-year primary patency rate compared with the diabetes mellitus cohort, 53% 
versus 82% (p < 0.02). However, the limb salvage rate for the DM+ESRD and DM 
cohorts during the same time interval were not significantly different, 63% versus 84% 
(p < 0.06). The 52% 1-year survival rate for the DM+ESRD cohort was strikingly lower 
than the 90% 1-year survival rate for the DM cohort (p < 0.002). 
Conclusion: Despite the use of the optimal autogenous conduit, the combination of dia- 
betes and end-stage renal disease can be expected to significantly decrease primary graft 
patency without affecting limb salvage. The greatest effect of these comorbid factors is 
on patient survival. (J Vase Surg 1998;27:1049-55.) 
Several investigators have reported encouraging 
results of lower-extremity ibial arterial reconstruc- 
tion among patients with diabetes and critical limb 
ischemia. 1-5 The operative mortality rate has ranged 
between 0% and 6% and the 1-year patient survival 
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rate between 82% and 89%. These procedures have 
yielded a 1-year primary patency rate of 76% to 86% 
and a limb salvage rate of  80% to 89%. Although 
these results have encouraged liberal infrageniculate 
reconstruction i the treatment of patients with dia- 
betes, the perioperative morbidity rate remains for- 
midable, ranging between 4% and 31%. 
In contrast, large series documenting the results 
of lower-extremity ibial arterial reconstruction i  
the treatment of  patients with diabetes and end- 
stage renal disease (ESRD) are lacldng. Most pub- 
lished reports contain small series of  patients with 
renal insufficiency, a functioning renal transplant, or 
dialysis-dependent renal failure.3, 7-12 In addition, 
tibial reconstructive procedures vary in both conduit 
used and level of  distal arterial anastomosis. The 
results of these procedures have been disappointing. 
Both operative and 1-year mortality rates are 
extremely high, ranging between 5% and 13% and 
57% and 74%, respectively. Perioperative morbidity 
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Table I. Demographic characteristics and risk 
factors for 83 in situ femorotibial bypass grafts 
among 76 patients 
DM 
Characteristic DM plus ESRD 
No. of patients 53 (70)* 23 (30) 
No. of primary procedures 58 (70)* 25 (30) 
Age (yr; mean value + SEM) 68 + 1.5 65 ± 112 
Sex (no. of patients) 
Female 5 (9) 6 (24) 
Male 48 (91) 17 (76) 
Dialysis (no. of patients) 
Hemodialysis _ 23 (92) 
Peritoneal _ 2 (8) 
Risk factors (no. of patients) 
Hypertension 40 (76) 14 (61) 
Coronary artery disease 23 (44) 10 (43) 
Stroke 8 (15) 3 (13) 
Cigarette smoking 30 (57) 17 (74) 
Values in parentheses are percentages. 
*p = 0.007. 
rates vary greatly, ranging between 0% and 47%. 
Somewhat encouraging are reported 1-year primary 
patency and limb salvage rates of 71% to 89% and 
70% to 90%, respectively. 1-5 
It is not surprising that wide variations in out- 
come have been reported in these small series, given 
the heterogenous group f atients and procedures 
undertaken. In an attempt to clarify the contribution 
of ESRD to the outcome of femorotibial reconstruc- 
tion in the treatment of patients with diabetes and 
critical imb ischemia, this study was undertaken. 
METHODS 
Patients were found through a computerized 
registry of vascular surgical procedures performed 
between August 1992 and January 1997 at the 
University Hospital and Boston Veterans Affairs 
Medical Center, both teaching components of the 
Boston University surgical residency program. 
Patients were determined to have a preoperative 
diagnosis of diabetes only (DM) or diabetes and 
ESRD (DM+ESRD) necessitating chronic dialytic 
therapy and critical lower extremity ischemia. A ret- 
rospective chart review of 280 lower-extremity arte- 
rial bypass procedures in this 5-year period revealed 
83 (30%) primary femorotibial in situ reconstruc- 
tions, five of which were bilateral, among 76 
patients with DM or DM+ESRD. In an attempt to 
define a subset of patients with similar conduits and 
surgical techniques for analysis, combined inflow, 
composite vein, reversed vein, transposed vein, 
prosthetic, pedal, secondary, and tertiary recon- 
structions were excluded. Table I represents demo- 
graphic characteristics and risk factors for these 
patients. There were significantly more patients, 
and therefore procedures, in the DM cohort com- 
pared with the DM+ESRD cohort. 
The DM cohort included patients with a prior 
diagnosis of diabetes mellitus. All patients had a cur- 
rent or past requirement for insulin or oral hy- 
poglycemic therapy. In most instances, ESRD was 
presumed to be a complication of diabetes. Othcr 
causes necessitating renal biopsy, such as glomeru- 
losclerosis or membranous nephropathy, were not 
excluded, because most patients had atrophic kid- 
neys and ESRD. Patients with functioning renal 
transplants were excluded from the study. 
All procedures involved the greater saphenous 
vein and in situ technique of arterial reconstruction. 
Most proximal anastomoses (DM 67%; DM+ESRD 
68%) originated at the common femoral artery. In 
the other procedures, anastomoses originated from 
the proximal (DM 29%; DM+ESRD 28%) or from 
the distal (DM 4%; DM+ESRD 3%) superficial 
femoral artery. Distal nastomoses in most instances 
(DM 55%; DM+ESRD 60%) were located at the 
posterior tibial artery. The others were divided 
approximately equally between the anterior tibial 
and peroneal arteries. Preoperative and completion 
arteriography was performed in all instances. 
Postoperative graft surveillance included pulse 
volume recording or duplex ultrasound examination 
or both before discharge followed by examinations 
at 3-month to 6-month intervals. All patients were 
available for follow-up data collection. Graft paten- 
cy, limb salvage, and survival rates were determined 
by means of Kaplan-Meier analysis and log-rank test, 
expressed as mean value _+ SEM. Grafts that occlud- 
ed or necessitated revision of any kind were regard- 
ed as occluded in accordance with the published 
standards for reporting the r sults of vascular econ- 
struction. 13 Patient variables were compared by 
means of chi-square and Fisher exact est, and mul- 
tivariate analysis was performed with the Cox pro- 
portional hazard model. 
RESULTS 
The primary preoperative diagnosis was deter- 
mined to be the chief symptom that resulted in pre- 
sentation for vascular surgical care. Infection was 
defined as active purulence, myonecrosis, orsoft-tis- 
sue liquefaction. The active process was limited to 
the plantar aspect of the heel or forefoot, resulting in 
less than approximately 5 cm circumference tissue 
destruction. 
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Table II. Primary preoperative diagnosis for 83 in situ femorotibial bypass grafts among 76 patients 
Preoperative diagnosis DM DM plus ESRD p Value 
Infection 10 (17) 8 (32) 0.14 
Tissue loss and dry gangrene 19 (33) 13 (52) 0.10 
Rest pain 26 (45) 4 (16) 0.02 
Clandication and acute ischemia 3 (5) - -  - -  
Values in parentheses are percentages. 
Analysis of preoperative diagnosis with the num- 
ber of procedures as the denominator revealed that 
rest pain was significantly more frequent among the 
DM cohort (Table II). Thirty-day morbidity and 
mortality rates did not demonstrate a significant dif- 
ference in wound or systemic omplications or early 
graft thrombosis between cohorts (Table III). Cel- 
lulitis was defined as erythema without drainage, 
leukocytosis, or fever. There was one perioperative 
fatal myocardial infarction, which resulted in a mor- 
tality rate of 1.2% for the entire series. 
Cumulative 1-year primary patency, limb salvage, 
and survival rates are compared in Table IV. The 
DM+ESRD cohort displayed asignificantly lower 1- 
year primary patency rate than the DM cohort, 53% 
versus 82% (p < 0.02). However, the limb salvage 
rates for the DM+ESRD and DM cohorts during 
the same time interval were not significantly differ- 
ent, 63% versus 84% (p < 0.06). 
The 52% 1-year survival rate for the DM+ESRD 
cohort was strikingly lower than the rate of 90% for 
the DM cohort (p < 0.002). In the DM+ESRD 
cohort, femorotibial reconstruction ultimately 
resulted in major amputation in 36% of instances, 
compared with 16% for the DM cohort (p = 0.03). 
Because the limb salvage rate was not significantly 
different, although a trend toward decreased limb 
salvagc in thc presence of ESRD was demonstrated, 
a type II or ~ error may have been present. There 
were no significant differences in time interval to 
amputation. Analysis of major amputations based on 
preoperative diagnosis did not reveal significant dif- 
ferences between the DM+ESRD and DM cohorts 
or within each cohort (Table V). 
In both the DM+ESRD and DM cohorts, nine 
major amputations were performed, in each group 
seven were below the knee. Two (3%) perioperative 
graft occlusions occurred in the DM cohort. Late 
graft occlusions occurred among three patients (5%) 
in the DM cohort and three patients (12%) in the 
DM+ESRD cohort. These differences were not sig- 
nificant. Overall, graft thrombosis occurred among 
10% of patients. Graft ligation at major amputation 
Table III. Thirty-day morbidity and mortality 
rates for 83 in situ femorotibial bypass grafts 
among 76 patients 
DM DM 
Variable (n = 58) plus ESRD (n = 25) 
Wound complications 14 (24) 4 (17) 
Cellulitis 4 (7) - -  
Infection 6 (10) 2 (8) 
Hematoma, seroma 4 (7) 2 (8) 
Systemic omplications 18 (31) 10 (40) 
Pneumonia 6 (15) 4 (16) 
Respiratory failure 1 (2) 1 (4) 
Nonfatal myocardial 2 (3) 
infarction 
Graft thrombosis 2 (3) - -  
30-day mortality 1 (2) - -  
Values in parentheses are percentages. 
for progression of infection despite successful re- 
vascularization was required in five instances (6%). 
Ligation of a patent graft at amputation was per- 
formed on four patients (16%) in the DM+ESRD 
cohort with only one patient (2%) in the DM cohort 
(p < 0.03). 
One-year mortality from cardiovascular events 
occurred among 75% of the DM+ESRD cohort and 
50% of the DM cohort (p < 0.40). Pneumonia nd 
chronic obstructive pulmonary disease caused the 
other deaths. The overall mortality rate for the 
DM+ESRD cohort (48%) was significantly greater 
than that for the DM cohort (10%) (p < 0.008). 
Multivariate analysis revealed that both ESRD and 
the preoperative diagnosis of tissue loss correlated 
independently with decreased survival rate. Only 
ESRD was a predictor of decreased graft patency 
(Table VI). 
DISCUSSION 
The purpose of this study was to determine the 
effect of dialysis-dependent ESRD on the outcome 
of in situ femorotibial reconstruction i the treat- 
ment of patients with diabetes with critical limb 
ischemia. In this series, the DM and DM+ESRD 
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Table IV. Cumulative 1-year patency, limb salvage, and survival rates for 83 in situ femorotibial bypass 
grafts among 76 patients 
DM DM plus 
Variable (n = 58) ESRD (n = 25) p Value 
Graft patency rate (%) 82 _+ 4 53 + 13 0.02 
Limb salvage rate (%) 84 ± 6 63 + 6 0.06 
Patient survival rate (%) 90 ± 4 (n = 56) 52 _+ 12 (n = 23) 0.002 
Table V. Major amputation based on preoperative 
diagnosis for 83 in situ femorotibial bypass grafts 
among 76 patients 
Diabetes Diabetes mellitus 
Preoperative mellitus plus ESRD 
diagnosis (n = 58) (n = 25) p Value 
Infection 3 (30) 5 (63) 0.30 
Tissue loss 3 (16) 2 (15) 0.60 
Rest pain 3 (12) 2 (50) 0.19 
Claudication or 
acute ischemia - -  - -  - -  
Total 9 (16) 9 (36)* 0.03 
Values in parentheses are percentages. 
ESRD, End-stage renal disease. 
*p = 0.03. 
Table VI. Determinants of mortality and patency 
from multivariate analysis for 83 in situ femorotib- 
ial bypass grafts among 76 patients 
Odds 95% Confidence 
Multivariate ratio interval p Value 
Mortality 
End-stage 
renal disease 3.9 1.6-9.1 0.002 
Tissue loss 4.1 1.8-9.5 0.001 
Patency 
End-stage 
renal disease 3.0 1.1-8.1 0.03 
cohorts were similar in age; representing a some- 
what older population of patients than previously 
reported. However, resulting graft patency, limb 
salvage, peri-operative morbidity, and survival at 
one year are similar to published reports.2,9,1°, 12
Previously, a preoperative diagnosis of infection 
has been correlated with limb loss, in patients with 
ESRD+DM. 3 Thiscould not be confirmed in this 
study. Among patients with a preoperative diagnosis 
of infection, major amputation was required in 30% 
of DM and 63% of DM+ESRD. However the over- 
all rate of major amputation was greater for patients 
with DM+ESRD, 36% than the DM cohort, 16%, (p 
< 0.03). 
In this study, 1-year primary patency for the DM 
and DM+ESRD cohorts were 82% and 53%, respec- 
tively. During the earlier years of the study, graft sur- 
veillance was based upon pulse volume recording 
and ankle to brachial pressure determination. This 
may have contributed to a delay in intervention. At 
present duplex ultrasound examination of the entire 
graft is performed before discharge and at 3-month, 
6-month, and annual follow-up visits. 
Ligation of a patent femorotibial graft at the 
time of amputation for progression of distal foot 
infection has been described for 18% to 25% of 
patients with DM+ESRD.7,12 This has lead to con- 
sideration of primary amputation for patients with 
DM+ESRD who have large (>4 cm) infected foot 
ulcers. 7 In this series, ligation of a patent graft at 
amputation for a nonhealing foot lesion was per- 
formed more frequently for patients in the 
DM+ESRD cohort, 4 of 25 (16%), than in the DM 
cohort 1 of 58 (2%). In all instances, ligation was 
needed by patients with a foot infection and result- 
ed in limb loss. Although in retrospect distal arterial 
reconstruction may have been undertaken when 
limbs were "unsalvageable," this possibility was not 
obvious after extensive debridement before estab- 
lishment of arterial supply and antibiotic therapy. 
Had a policy of primary amputation been used for 
the preoperative diagnosis of foot infection, among 
patients in the DM+ESRD cohort, the limb loss rate 
would have been 48% versus 36%. 
In this study, the presence of ESRD significantly 
diminished 1-year primary patency and survival rates 
among patients with diabetes. The mechanism of 
decreased graft patency remains unclear. It has been 
established that, in patients with non-insulin-depen- 
dent diabetes, nitric oxide-mediated vasodilatation 
is impaired. 14 Studies have documented increased 
peripheral vascular esistance and decreased saphe- 
nous vein endothelial prostaglandin production 
among patients with diabetes in comparison with 
patients without diabetes.iS, 16Although these alter- 
ations alone would not explain diminished graft 
patency among patients with DM+ESRD, increased 
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levels of the vasoconstrictor peptide ndothelin have 
been documented among patients with chronic 
renal failure. 17 These levels are not affected by long- 
term hemodialysis. It is speculated that the additive 
effect of these cellular alterations may have a nega- 
tive effect on graft patency. 
Encouraging results of nonoperative therapy 
among patients with ESRD and symptomatic coro- 
nary and peripheral vascular disease have been 
reported. Low-dose intermittent thrombolytic ther- 
apy reportedly decreased myocardial ischemia and 
rest pain among 50% to 70% of patients. 18 Given the 
diminished graft patency and life expectancy among 
patients with DM+ESRD, further investigation of 
such nonoperative therapy appears justified. 
Initial reports questioned whether patients with 
ESRD display accelerated progression of peripheral 
vascular disease. The advancement of vascular calci- 
fication among these patients has been demonstrat- 
ed to continue independently of successful renal 
transplantation. 19 Another study did not demon- 
strate accelerated atheroma development among a 
combined population of patients undergoing long- 
term chronic hemodialysis or renal transplanta- 
tion. 2° Successful combined kidney and pancreas 
transplantation has been reported to accelerate 
peripheral vascular disease, zl Successful renal trans- 
plantation has been shown to decrease the mortality 
rate after lower-extremity amputation for critical 
limb ischemia, z2 
In this study, the main cause of late mortality was 
coronary artery disease, which accounted for 50% 
and 75% of deaths in the DM and DM+ESRD 
cohorts, respectively. A preoperative history of coro- 
nary artery disease was present among 44% of 
patients in the cohort DM and 43% of patients in the 
DM+ESRD cohort. These fatal events occurred 
despite formal preoperative cardiac evaluation, 
which consisted at minimum of dipyridamole-thalli- 
um stress testing or dobutamine stress echocardiog- 
raphy. The adequacy of such evaluation may be 
defined by a rate of perioperative nonfatal myocar- 
dial infarction of 2.6% (2 of 76 patients) and only 
one fatal myocardial infarction (1.3%). The some- 
what advanced age of the patients in this study and 
accelerated atherogenesis in ESRD may account in
part for the high cardiac mortality rate reported. 
In this study, the negative ffect of ESRD and 
presentation with tissue loss on patient survival was 
striking. Although one may have presumed that 
infection would have a negative ffect on survival, 
the chronicity of tissue loss may define advanced 
underlying coronary artery disease. Given a I-year 
survival rate of 52%, prophylactic vascular surgical 
procedures, such as carotid endarterectomy for 
asymptomatic stenosis, which have been demon- 
strated to be beneficial in the treatment of patients 
with diabetes with a life-expectancy more than 5 
years, may not be justified in the care of most older 
patients with ESRD.23, 24 
It is clear that the addition of end-stage renal fail- 
ure to diabetes ignificantly diminishes primary graft 
patency and survival rates and may increase limb loss 
rate compared with the situation for age-matched 
patients with diabetes only. Although the preopera- 
tive diagnosis of infection was not a significant deter- 
minant of subsequent amputation between cohorts, 
significantly fewer grafts were ligated at amputation 
for progressive infection among patients with DM 
compared with those with DM+ESRD, 4% vs 2%. 
Had a policy of primary amputation in the care of 
patients with DM, ESRD, and infection been 
applied, the major amputation rate would have 
increased from 36% to 48%. Despite improvements 
in vascular surgical techniques and perioperative 
care, the older population of patients with DM, 
ESRD, and critical ischemia represents a continuing 
challenge. 
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DISCUSSION 
Dr. Peter N. Madras (Beverly, Mass.). I have a question, 
and then perhaps you will indulge me with a comment. The 
question stems from my experience in the last 20 years trug- 
gling with end-stage r nal patients with vascular disease. I 
wonder if you noticed any difference in outcome that is 
dependent on the length of time the patients have been on 
dialysis. It is my impression that if someone has been on dial- 
ysis for a long time they have significantly worse outcome. 
I would like to make one comment about the role of 
transplantation i  these patients. As you indicated, it 
appears that renal transplantation does not protect for 
long-term improved outcome. However, certainly the sur- 
vival rate of patients with successful renal transplantation is 
better than the survival rate that you showed with end- 
stage renal disease. 
Finally, the paper that we presented to the New Eng- 
land Society for Vascular Surgery last year surprisingly 
showed that successful pancreatic transplantation, such 
that these patients are no longer either diabetic or with 
end-stage renal disease, appears to significantly worsen the 
outcome of vascular reconstruction. 
Dr. Albert G. Hakalm. We did not look specifically at 
the duration that the patient was on dialysis, although 
your point is well taken. Indeed, patients on peritoneal 
dialysis are known to have exacerbations of their peripher- 
al vascular disease, which is thought o be more caused by 
hemodynamic fluctuations than to any differences in their 
peripheral vascular disease. Howcver, I am sure that you 
are aware that patients who have acute renal failure, such 
as bilateral renal cell carcinoma resections, and require any 
type of vascular surgery do extremely well compared with 
patients who have been on chronic dialysis. 
Dr. Frank B. Pomposel l i  (Boston, Mass.). We have 
looked at this issue from another perspective, and I won- 
der if you might comment. A few years ago, one of our fel- 
lows looked at the role of calcification of the blood vessels 
on outcome of lower extremity bypass graft. This fellow 
found that, in patients with heavily circumferentially calci- 
fied unclampable arteries, the outcomes were reasonably 
good but significantly worse than in those without calcP 
fled arteries. Calcified arteries are commonly seen in 
patients with end-stage renal disease and vascular disease. 
Did you look at the calcification of vessels as another pos- 
sible predictor of worse outcome? 
Dr. Hakaim. We did not look at that specifically. How- 
ever, there are several reports that apparently indicate that, 
with their techniques, they have been able to construct 
distal anastomoses in circumferential calcification and their 
results were equivalent. From my experience, although I 
do not have any data for this, the calcified vessels do not 
do as well. 
Dr. James M. Estes (Boston, Mass.). I would like to 
add a point in regards to additional therapies that we can 
offer these patients. I have observed good results in select- 
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ed patients with tibial artery angioplasty. For this group of 
patients with a limited life expectancy, the durability of 
percutaneous transluminal angioplasty is probably more 
appropriate to that particular group and may be especially 
applicable for those patients with severe rest pain. 
Dr. Hakaim. We have stayed away from that concept 
in this particular group of patients because of the calcifica- 
tion in these arteries. 
Dr. Joel A. Berman (Springfield, Mass.). I have two 
questions. First, did you attempt o grade the severity of 
disease in the two groups and the status of the outflow 
vessels? Second, because most of these patients died a car- 
diovascular death, have you presented this data to your 
cardiac surgeons to see whether or not these patients 
should have been considered for bypass urgery? 
Dr. Hakaim. Those are two good questions. Let me 
answer the second one first. As you are probably aware, 
the results of coronary artery bypass grafting in patients 
with renal failure and diabetes are not very good. So, car- 
diac surgeons are not anxious to get involved with the 
patients. However, coronary angioplasty may find an 
increasing role in those patients. 
We did not grade the severity of the disease. The distal 
vessel used for anastomosis, between tibial vessels, was the 
vessel that had continuity into the foot or the peroneal. 
Dr. Jack L Cronenwett (Lebanon, N.H.). This is a nice 
presentation and certainly one of the larger, if not the 
largest, series of these patients, and these series are difficult. 
My question relates to your application of these results to 
your current and future practice in deciding whether to per- 
form bypass urgery in these patients. First, I wonder if you 
can tell us how selected your population was. Clearly, there 
are a complete spectrum of patients with dialysis-dependent 
renal failure, and I am sure you applied some selection cri- 
teria even to get this group. I realize that you did not have 
any statistically significant indicators of graft outcome in 
your renal failure group, but do you have any current clini- 
cal guidelines that you use to decide which patients with 
dialysis-dependent renal failure will receive bypass graft? 
Dr. Hakaim. The patient selection was broad. The 
only preoperative selection criterion was that the patient 
be ambulatory before surgery. I think that was an advan- 
tage in this study. It allowed us to look at a much greater 
group of patients than we would have if we had applied 
selection criteria. 
Dr. Robert B. Patterson (Providence, R.I.). I may 
have missed the rationale, but did you exclude pedal 
bypass graft in this population? 
Dr. Hakaim. Yes, we did exclude pedal bypass graft in 
this study. 
Dr. Patterson. I do not understand why you excluded 
this. The majority of our patients with these problems had 
pedal bypass, and it is unusual for us to go more proximal 
than that. Could I ask you to comment on this? 
Dr. Itakaim. We did not have a large series of patients 
with pedal bypass grafts in both groups. Most of our pedal 
bypass grafts were performed in patients with diabetes and 
end-stage renal disease. So, to comparable groups with 
the same conduit, we chose to look at our in situ tibial 
reconstructions. 
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